A., Taylor, M. H., Mahadevan, D., Lockhart, A. C., Vaishampayan, ...> ;The oncologist. Pishvaian MJ, Bender RJ, Halverson D, Rahib L, Hendifar AE, Mikhail S, Chung V, Picozzi VJ, Sohal D, Blais EM, Mason K, Lyons EE, Matrisian LM, Brody JR, Madhavan S, Petricoin EF. 2018 Mar 27, Segal, N. H., He, A. R., Doi, T., Levy, R., Bhatia, S., Pishvaian, M. J., Cesari, R., Chen, Y., Davis, C. B., Huang, B., Thall, A. D., Gopal, A. K.> ;Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Aug 9, Dhir, T., Schultz, C. W., Jain, A., Brown, S. Z., Haber, A., Goetz, A., Xi, C., Su, G. H., Xu, L., Posey, J., Jiang, W., Yeo, C. J., Golan, T., Pishvaian, M. J., Brody...> ;Molecular cancer research : MCR. Profiles may include costs for specific services and procedures, common referrals, ratings, and reviews. His credentials are: MD (Doctor of Medicine).He graduated from Georgetown University Of Medicine in 2001 (around 19 years of experience). Group Hospitalization and Medical Services Inc. We'd really appreciate it if you're able to take a moment to leave your thoughts and feedback if you have had an office visit or appointment with Dr. Michael Pishvaian MD. He is affiliated with University of Texas M.D. Psychologists He is also the Director of the Phase I Clinical Trial Program at Lombardi. Aiwu Ruth He, Anteneh Tesfaye, Daniel Smith, John Marshall, Michael J. Pishvaian, Brandon George Smaglo, Louis M. Weiner, Karen Dorsch-Vogel, and Hongkun Wang., ASCO MEETING ABSTRACTS, 1/27/2014. [Epub ahead of print] PMID: 29954777, Brar G, Blais EM, Joseph Bender R, Brody JR, Sohal D, Madhavan S, Picozzi VJ, Hendifar AE, Chung VM, Halverson D, Mikhail S, Matrisian LM, Rahib L, Petricoin E, Pishvaian MJ. A randomized, open-label phase II study of efatutazone in combination with FOLFIRI as second-line therapy for metastatic colorectal cancer (mCRC).
Dr. Michael Pishvaian is the director of Gastrointestinal, Developmental Therapeutics and Clinical Research Programs for the Johns Hopkins Kimmel Cancer Center in the Greater Washington Area and an associate professor at the School of Medicine. Click here to learn more about oncology clinical trials the Greater Washington Area. Association of DNA damage response and repair genes (DDR) mutations and microsatellite instability (MSI), PD-L1 expression, tumor mutational burden (TMB) in gastroesop... Michael Cerniglia, Joanne Xiu, Axel Grothey, Michael J. Pishvaian, Jimmy J. Hwang, John Marshall, Ari M. Vanderwalde, Anthony Frank Shields, Heinz-Josef Lenz, Mohamed ..., Gastrointestinal Cancers Symposium, J Clin Oncol, 1/1/2019. Patients are de-identified for confidentiality and patient privacy. Genetic Drivers of Pancreatic Cancer Are Identical Between the Primary Tumor and a Secondary Lesion in a Long-Term (>5 Years) Survivor After a Whipple Procedure. 2017 Mar 3, Rao, S., Beckman, R. A., Riazi, S., Yabar, C. S., Boca, S. M., Marshall, J. L., Pishvaian, M. J., Brody, J. R., Madhavan, S.> ;Oncotarget. Dr. Michael Pishvaian graduated from Georgetown University Of Medicine in 2001. WebMD does not provide medical advice, diagnosis or treatment. 2019 Jul 12, Tesfaye, A. A.,Wang, H.,Hartley, M. L.,He, A. R.,Weiner, L.,Gabelia, N.,Kapanadze, L.,Shezad, M.,Brody, J. R.,Marshall, J. L.,Pishvaian, M. J.> ;J Pancreat Cancer. 2017 Jul 9, Ott, P. A., Bang, Y., Berton-Rigaud, D., Elez, E., Pishvaian, M. J., Rugo, H. S., Puzanov, I., Mehnert, J. M., Aung, K. L., Lopez, J., Carrigan, M., Saraf, S., Chen, M...> ;Journal of clinical oncology : official journal of the American Society of Clinical Oncology. doi: 10.1158/1078-0432.CCR-18-0531. A cloud-based virtual tumor board to facilitate treatment recommendations for patients with advanced cancers. Multiplatform profiling of pancreatic neuroendocrine tumors: Correlative analyses of clinicopathologic factors and identification of co-occurring pathogenic alterations. Anderson Cancer Center. His credentials are: MD (Doctor of Medicine). 00115, Pishvaian MJ, Blais EM, Bender RJ, Rao S, Boca SM, Chung V, Hendifar AE, Mikhail S, Sohal DPS, Pohlmann PR, Moore KN, He K, Monk BJ, Coleman RL, Herzog TJ, Halverson DD, DeArbeloa P, Petricoin EF 3rd, Madhavan S. A virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patients. Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. Marie Kate Gurka, Christine M Kim, Nadim G Haddad, John Carroll, Aline C Charabaty, Patrick G Jackson, K. William Harter, Jimmy J. Hwang, Louis M. Weiner, John Marshal..., ASCO MEETING ABSTRACTS, 1/27/2014. He is affiliated with University of Texas M.D. A phase I study of the BCR-ABL tyrosine kinase inhibitor nilotinib and cetuximab in patients with solid tumors that can be treated with cetuximab. Phase III, randomized, double blind, placebo-controlled trial of sorafenib in desmoid tumors (Alliance A091105). Dr. Michael Pishvaian is an Assistant Professor, GI Medical Oncology at the University of Texas MD Anderson Cancer Center. Medstar Montgomery Medical Center. Multi-omic molecular comparison of primary versus metastatic pancreatic tumours. Clin Cancer Res. Dentists 2018 Mar 20, Pishvaian, M. J., Bender, R. J., Matrisian, L. M., Rahib, L., Hendifar, A. E., Hoos, W. A., Mikhail, S., Chung, V., Picozzi, V. J., Heartwell, C., Mason, K., Varieur, ...> ;Oncotarget. Our Full Ratings Survey includes 3 main topics and 9 questions including staffing, wait times, appointment scheduling, billing, and more.
Find Dr. Pishvaian's phone number, address, hospital affiliations and more. 2017 Update in Gastrointestinal Cancer: What are the New Strategies?
Brandon George Smaglo, Hongkun Wang, Kenneth Steadman, Joseph Murray, Michael Pishvaian, Aiwu Ruth He, Jimmy J. Hwang, Deepa Suresh Subramaniam, John F. Deeken, and Lo..., ASCO MEETING ABSTRACTS, 1/17/2013. Dr. Michael Pishvaian MD's practice location is: 1515 Holcombe Blvd Houston, TX 77030. 2017 May 11, Ott, P. A.,Piha-Paul, S. A.,Munster, P.,Pishvaian, M. J.,van Brummelen, EMJ.,Cohen, R. B.,Gomez-Roca, C.,Ejadi, S.,Stein, M.,Chan, E.,Simonelli, M.,Morosky, A.,Saraf, ...> ;Ann. A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Know Your T... Posttranscriptional Regulation of PARG mRNA by HuR Facilitates DNA Repair and Resistance to PARP Inhibitors. 2017 Jan 04, Pishvaian, M. J., Slack, R. S., Jiang, W., He, A. R., Hwang, J. J., Hankin, A., Dorsch-Vogel, K., Kukadiya, D., Weiner, L. M., Marshall, J. L., Brody, J. R.> ;Cancer. A phase I/II study of ribociclib plus everolimus in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) refractory to chemotherapy. 2019 Feb 23, Jansen, V. M., Bhola, N. E., Bauer, J. 2019 Sep 21, Weinberg, B.
Dr. Michael Pishvaian is a Oncologist in Washington, DC. 2018 Sep 21, Pishvaian, M. J., Pishvaian, M. J., Pishvaian, M. J., Pishvaian, M. J., Bender, R. J., Bender, R. J., Bender, R. J., Bender, R. J., Halverson, D., Halverson, D., Halve...> ;Clinical cancer research : an official journal of the American Association for Cancer Research. JCO Precis Oncol. The Pros and Cons of Expanded Carrier Screening wi... Is This A Unique Time for Science? Molecular Profiling of Pancreatic Cancer Patients-Response. Get cell phone / mobile directions from your current location: To get more traditional directions enter a starting address below: Saswati N. Chand , Mahsa Zarei , Akshay R. Kamath, Matthew J. Schiewer, Carmella Romeo, Joseph A. Cozzitorto, Eric Londin, Isidore Rigoutsos, Wei Jiang, Nicole Meisner..., AACR, 1/1/2016. Oncol.. 2017 Apr 30, Frankel, A. E., Flaherty, K. T., Weiner, G. J., Chen, R., Azad, N. S., Pishvaian, M. J., Thompson, J.
He lists the following medical group affiliations: Medstar Georgetown Medical Center, Inc. His hospital privileges include: Medstar Georgetown University Hospital, Molecular Profiling of Pancreatic Cancer Patients: Initial Results from the Know Your Tumor Initiative.
Stereotactic body radiation therapy (SBRT) combined with chemotherapy for locally advanced pancreatic adenocarcinoma. Medicare Participation: He lists the following medical group affiliations: Medstar Georgetown Medical Center, Inc. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. registered in the U.S. and other countries. School: GEORGETOWN UNIVERSITY OF MEDICINE, Houston with Medical Oncology Internal Medicine, TX Medical Oncology Internal Medicine Listings. He graduated from Georgetown University Of Medicine in 2001 (around 19 years of experience). Dr. Michael Pishvaian is a Medical Oncology Specialist in Washington, District Of Columbia.
He has 19 years of experience. Please consider filling out our survey via the link below to help future patients make an informed decision. Dr. Michael Pishvaian is an Assistant Professor in Hematology/Oncology at the Lombardi Comprehensive Cancer Center, Georgetown University. Dr. Michael Pishvaian MD is a male health care provider in Houston with Medical Oncology Internal Medicine listed as his primary medical specialization. Rating Overview 9 Ratings with 5 Comments 4.1 The overall average patient rating of Michael J Pishvaian is Great.